181 related articles for article (PubMed ID: 18636402)
1. Discovery of myopodin methylation in bladder cancer.
Cebrian V; Alvarez M; Aleman A; Palou J; Bellmunt J; Gonzalez-Peramato P; Cordón-Cardo C; García J; Piulats JM; Sánchez-Carbayo M
J Pathol; 2008 Sep; 216(1):111-9. PubMed ID: 18636402
[TBL] [Abstract][Full Text] [Related]
2. Identification of PMF1 methylation in association with bladder cancer progression.
Aleman A; Cebrian V; Alvarez M; Lopez V; Orenes E; Lopez-Serra L; Algaba F; Bellmunt J; López-Beltrán A; Gonzalez-Peramato P; Cordon-Cardo C; García J; del Muro JG; Esteller M; Sánchez-Carbayo M
Clin Cancer Res; 2008 Dec; 14(24):8236-43. PubMed ID: 19088041
[TBL] [Abstract][Full Text] [Related]
3. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer.
Alvarez-Múgica M; Cebrian V; Fernández-Gómez JM; Fresno F; Escaf S; Sánchez-Carbayo M
J Urol; 2010 Oct; 184(4):1507-13. PubMed ID: 20723929
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome.
Sanchez-Carbayo M; Schwarz K; Charytonowicz E; Cordon-Cardo C; Mundel P
Oncogene; 2003 Aug; 22(34):5298-305. PubMed ID: 12917631
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic utility of methylation and protein expression patterns of myopodin in colon cancer.
Esteban S; Moya P; Fernandez-Suarez A; Vidaurreta M; González-Peramato P; Sánchez-Carbayo M
Tumour Biol; 2012 Apr; 33(2):337-46. PubMed ID: 22252522
[TBL] [Abstract][Full Text] [Related]
6. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
8. DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis.
Nakagawa T; Kanai Y; Ushijima S; Kitamura T; Kakizoe T; Hirohashi S
J Urol; 2005 May; 173(5):1767-71. PubMed ID: 15821584
[TBL] [Abstract][Full Text] [Related]
9. Progressive increases in de novo methylation of CpG islands in bladder cancer.
Salem C; Liang G; Tsai YC; Coulter J; Knowles MA; Feng AC; Groshen S; Nichols PW; Jones PA
Cancer Res; 2000 May; 60(9):2473-6. PubMed ID: 10811126
[TBL] [Abstract][Full Text] [Related]
10. Promoter analysis of epigenetically controlled genes in bladder cancer.
Veerla S; Panagopoulos I; Jin Y; Lindgren D; Höglund M
Genes Chromosomes Cancer; 2008 May; 47(5):368-78. PubMed ID: 18196590
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation identifies progression risk in bladder cancer.
Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
[TBL] [Abstract][Full Text] [Related]
12. DBC2 gene is silenced by promoter methylation in bladder cancer.
Shi Y; Chen JY; Yang J; Li B; Chen ZH; Xiao CG
Urol Oncol; 2008; 26(5):465-9. PubMed ID: 18640857
[TBL] [Abstract][Full Text] [Related]
13. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
[TBL] [Abstract][Full Text] [Related]
14. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
15. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells.
Ikeda JI; Morii E; Kimura H; Tomita Y; Takakuwa T; Hasegawa JI; Kim YK; Miyoshi Y; Noguchi S; Nishida T; Aozasa K
J Pathol; 2006 Sep; 210(1):75-84. PubMed ID: 16823897
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.
Reinert T; Modin C; Castano FM; Lamy P; Wojdacz TK; Hansen LL; Wiuf C; Borre M; Dyrskjøt L; Orntoft TF
Clin Cancer Res; 2011 Sep; 17(17):5582-92. PubMed ID: 21788354
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
Ellinger J; El Kassem N; Heukamp LC; Matthews S; Cubukluoz F; Kahl P; Perabo FG; Müller SC; von Ruecker A; Bastian PJ
J Urol; 2008 Jan; 179(1):346-52. PubMed ID: 18006010
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
